CLGN - CollPlant Biotechnologies Ltd
Previous close
3.6
-1.000 -27.778%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:21:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$4.60
-1.00
-21.74%
Fundamental analysis
14%
Profitability
18%
Dept financing
18%
Liquidity
54%
Performance
0%
Performance
5 Days
2.64%
1 Month
-17.79%
3 Months
-26.81%
6 Months
-31.37%
1 Year
-32.17%
2 Year
-58.03%
Key data
Stock price
$3.60
DAY RANGE
$3.58 - $4.60
52 WEEK RANGE
$3.60 - $6.75
52 WEEK CHANGE
-$46.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/21/2024
Company detail
CEO: Yehiel Tal
Region: US
Website: collplant.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: collplant.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
CollPlant Biotechnologies Ltd. focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie.
Recent news